Sugi Predict

Sugi Predict / Compounds / SCHEMBL623299

SCHEMBL623299

SCHEMBL623299

CC1(C)OB(c2cnc(N)nc2C(F)(F)F)OC1(C)C

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.39
▸ NR1H2 P55055 1/20 0.37
▸ NR1H3 Q13133 1/20 0.37
▸ PIK3CA P42336 5/20 0.36
▸ MTOR P42345 5/20 0.36
▸ PIK3CB P42338 2/20 0.36
▸ PIK3CD O00329 1/20 0.36
▸ PIK3C2B O00750 1/20 0.36
▸ PIK3R1 P27986 1/20 0.36
▸ PIK3CG P48736 1/20 0.36
▸ PIK3C3 Q8NEB9 1/20 0.36
▸ PI4KB Q9UBF8 1/20 0.36
▸ LIPE Q05469 4/20 0.33
▸ RPTOR Q8N122 1/20 0.31
▸ MLST8 Q9BVC4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15676427 0.98 KDM4E (0.38) KDM4ENR1H2NR1H3PIK3CAMTOR
SCHEMBL30606415 0.79 NR1H2 (0.38) NR1H2NR1H3LIPE
SCHEMBL26658314 0.79 NR1H2 (0.38) NR1H2NR1H3LIPE
SCHEMBL30606424 0.79 NR1H2 (0.38) NR1H2NR1H3LIPE
SCHEMBL26658298 0.79 NR1H2 (0.38) NR1H2NR1H3LIPE
SCHEMBL856951 0.79 DHFR (0.34) —
SCHEMBL1114281 0.78 RXFP1 (0.33) PIK3CAMTORPIK3R1
SCHEMBL16027854 0.77 NR1H2 (0.34) NR1H2NR1H3LIPE
SCHEMBL13449514 0.76 NUDT1 (0.33) —
SCHEMBL15814443 0.74 NUDT1 (0.33) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2991978-B1 BIHETEROARYL COMPOUNDS AND USES THEREOF F HOFFMANN LA ROCHE SA (CH) 2025-08-20 — — EP disclosed
WO-2025100970-A1 TNAP INHIBITORY COMPOUND AND USE THEREOF 주식회사 레드엔비아 2025-05-15 — — WO disclosed
CN-117777042-B Triazine hydroxamic acid derivative and preparation method and application thereof 长沙医学院 2025-01-24 — — CN disclosed
CN-117777042-A Triazine hydroxamic acid derivative and preparation method and application thereof 长沙医学院 2024-03-29 — — CN disclosed
EP-3475285-B1 MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF SUZHOU KINTOR PHARMACEUTICALS INC (CN) 2022-02-09 — — EP disclosed
US-11242346-B2 Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) 2022-02-08 — — US disclosed
US-11129832-B2 Biheteroaryl compounds and uses thereof GENENTECH, INC. (US) 2021-09-28 — — US disclosed
US-20200188397-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2020-06-18 — — US disclosed
US-20200181147-A1 MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) 2020-06-11 — — US disclosed
US-20200171029-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2020-06-04 — — US disclosed
EP-2015734-A2 SOLID DOSAGE FORMULATIONS Wyeth (US) 2009-01-21 — — EP disclosed
EP-1989201-A1 PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE Novartis AG (CH) 2008-11-12 — — EP disclosed
EP-1984350-A1 PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS Novartis AG (CH) 2008-10-29 — — EP disclosed
US-20080242665-A1 1-(4-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticarcinogenic agent; F. HOFFMANN-LA ROCHE AG (CH) 2008-10-02 — — US disclosed
WO-2008098058-A1 PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2008-08-14 — — WO disclosed
WO-2008070740-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE F.HOFFMANN-LA ROCHE AG (CH) 2008-06-12 — — WO disclosed
WO-2007130438-A2 SOLID DOSAGE FORMULATIONS WYETH (US) 2007-11-15 — — WO disclosed
WO-2007095588-A1 PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2007-08-23 — — WO disclosed
WO-2007084786-A1 PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS NOVARTIS AG (CH) 2007-07-26 — — WO disclosed
WO-2007084786-A1 PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS NOVARTIS AG (CH) 2007-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11242346-B2 Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof MTOR, RPTOR, RICTOR KDM4E 2910/4885NR1H2 1319/4885NR1H3 1446/4885
US-11129832-B2 Biheteroaryl compounds and uses thereof BCHE, SNCA, HAX1 KDM4E 3436/4885NR1H2 141/4885NR1H3 152/4885
US-20200171029-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF BCHE, SNCA, XDH KDM4E 3228/4885NR1H2 140/4885NR1H3 145/4885
US-20200181147-A1 MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF MTOR, RPTOR, RICTOR KDM4E 2910/4885NR1H2 1319/4885NR1H3 1446/4885
US-20080242665-A1 1-(4-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticarcinogenic agent; PI4KA, DMPK, PDPK1 KDM4E 1909/4885NR1H2 463/4885NR1H3 495/4885
US-20200188397-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF BCHE, SNCA, HAX1 KDM4E 3436/4885NR1H2 141/4885NR1H3 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.